{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=15", "query": { "intervention": "Open Label Extension Study", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 2082, "total_pages": 209, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T14:59:53.144Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04041310", "title": "Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "GAd-209-FSP low dose", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP low dose", "type": "BIOLOGICAL" }, { "name": "GAd-209-FSP high dose", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP high dose", "type": "BIOLOGICAL" }, { "name": "GAd20-209-FSP, RP2D", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP, RP2D", "type": "BIOLOGICAL" }, { "name": "KEYTRUDA®", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nouscom SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2019-10-21", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-27T14:59:53.144Z", "location_count": 13, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04041310" }, { "nct_id": "NCT07336940", "title": "Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis (AD)" ], "interventions": [ { "name": "ENV-294 Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enveda Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 9, "start_date": "2025-09-10", "completion_date": "2026-01-13", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-27T14:59:53.144Z", "location_count": 5, "location_summary": "Fremont, California • Louisville, Kentucky • College Station, Texas + 2 more", "locations": [ { "city": "Fremont", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "College Station", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07336940" }, { "nct_id": "NCT04686136", "title": "A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Episodic Migraine", "Chronic Migraine" ], "interventions": [ { "name": "Atogepant 60 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 596, "start_date": "2021-02-19", "completion_date": "2025-10-20", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-10-27T14:59:53.144Z", "location_count": 42, "location_summary": "Phoenix, Arizona • Fresno, California • Los Alamitos, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04686136" }, { "nct_id": "NCT01789957", "title": "Extension Study for 2993-112", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "AC2993", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 225, "start_date": "2002-09", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2015-02-24", "last_synced_at": "2026-10-27T14:59:53.144Z", "location_count": 219, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 162 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Eclectic", "state": "Alabama" }, { "city": "Haleyville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01789957" }, { "nct_id": "NCT02921919", "title": "Open-Label Extension and Safety Study of Talazoparib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2016-11-08", "completion_date": "2021-07-20", "has_results": true, "last_update_posted_date": "2022-08-24", "last_synced_at": "2026-10-27T14:59:53.144Z", "location_count": 26, "location_summary": "Alhambra, California • Bakersfield, California • Burbank, California + 16 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02921919" }, { "nct_id": "NCT06937229", "title": "A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer Disease", "Agitation" ], "interventions": [ { "name": "KarXT", "type": "DRUG" }, { "name": "KarX-EC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "55 Years to 90 Years" }, "enrollment_count": 650, "start_date": "2025-12-02", "completion_date": "2029-07-20", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-27T14:59:53.144Z", "location_count": 42, "location_summary": "Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 37 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06937229" }, { "nct_id": "NCT07052903", "title": "TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Transthyretin Amyloidosis With Cardiomyopathy" ], "interventions": [ { "name": "Nucresiran", "type": "DRUG" }, { "name": "Sterile Normal Saline (0.9% NaCl)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 1750, "start_date": "2025-07-02", "completion_date": "2032-11-30", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-27T14:59:53.144Z", "location_count": 45, "location_summary": "La Jolla, California • Laguna Hills, California • Stanford, California + 38 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Norwich", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07052903" }, { "nct_id": "NCT00171158", "title": "An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Philadelphia Chromosome Positive CML" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "1999-07-26", "completion_date": "2013-04-22", "has_results": true, "last_update_posted_date": "2021-06-25", "last_synced_at": "2026-10-27T14:59:53.144Z", "location_count": 3, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00171158" }, { "nct_id": "NCT07841990", "title": "Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" }, { "name": "GS-3242", "type": "DRUG" }, { "name": "Lenacapavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2026-10-01", "completion_date": "2033-07", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-27T14:59:53.144Z", "location_count": 2, "location_summary": "Ft. Pierce, Florida • Houston, Texas", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07841990" }, { "nct_id": "NCT02106923", "title": "Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "1 tablet Empagliflozin/2 tablets Metformin XR", "type": "DRUG" }, { "name": "10 mg Empagliflozin/1000 mg Metformin XR", "type": "DRUG" }, { "name": "1 tablet 10 mg Empagliflozin/3 tablets Metformin XR", "type": "DRUG" }, { "name": "2 tablets 5 mg Empagliflozin/750 Metformin XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 72, "start_date": "2014-04", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-10-27T14:59:53.144Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02106923" } ] }